IMS Preview: 100% Response Rates and What's Next for Myeloma Care | Dr. Joshua Richter | IMS 2026

Dr. Joshua Richter from the Tisch Cancer Institute at Mount Sinai (Icahn School of Medicine) gives an on-the-ground preview of the major themes at the 2026 International Myeloma Society (IMS) meeting in Glasgow, from patient quality of life to the newest treatment data.

Dr. Richter previews the 100% response rates being reported with next-generation CAR-T cell therapies, new blood-based monitoring approaches (including circulating free DNA and soluble BCMA) that may reduce reliance on bone marrow biopsies, and why he expects relapsed/refractory myeloma to become less common as outcomes improve for newly diagnosed patients.

Timestamps:
0:00 Introduction: An IMS 2026 preview with Dr. Joshua Richter
0:12 Why "cure" is now part of the myeloma conversation
0:44 100% response rates with next-gen CAR-T therapies
0:59 Blood-based monitoring: a new approach to tracking disease
1:24 The future: rising cure rates in newly diagnosed patients

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.